Navigation Links
Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
Date:8/24/2007

PALO ALTO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that Mark A. Tarnopolsky, MD, PhD, FRCPC, professor at McMaster University in Hamilton, Ontario, Canada, presented a summary of findings demonstrating the positive effect of energy enhancing compounds for the potential treatment of neuromuscular diseases.

The findings were presented at the 10th International Congress on Amino Acids and Proteins (ICAAP) in Kallithea, Chalkidiki, Greece and is part of an ongoing collaborative program with Avicena to identify energy enhancing molecules as potential therapeutic agents for applications in neuromuscular diseases.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...IRMINGHAM, Ala., Nov. 9 ...hat it will host an investor conference call at 11..., to discuss its 2009 third quarter operating resu...ely an hour following the conclusion of the confer...cgi-bin/prnh/20080812/CLTU111LOGO ) ,, Pleas...
(Date:11/9/2009)...ATICK, Mass., Nov. 9 Bos...ounced its schedule of events at the 38th annual G...AAGL), which runs from November 15-19 in Orlando, ...e presented featuring the Company,s Urology/Gyneco...on systems and mid-urethral sling systems used to ...
(Date:11/9/2009)...EW YORK, Nov. 9 Keryx Bi...maceutical company focused on the acquisition, dev...ant pharmaceutical products for the treatment of l...al disease (the "Company"), today announced its re...09. ,, At September 30, 2009, the Company had c...
Breaking Medicine Technology:Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 2Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 3Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 4Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 6HealthFitness Named Lead Integrator for MillerCoors Health Improvement Program 54748 1HealthFitness Named Lead Integrator for MillerCoors Health Improvement Program 54748 2HealthFitness Named Lead Integrator for MillerCoors Health Improvement Program 54748 3Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 26 Type 2 Diabetes 54746 1Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 26 Type 2 Diabetes 54746 2Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 26 Type 2 Diabetes 54746 3Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 26 Type 2 Diabetes 54746 47 Easy Tips for Healthy Aging 54745 17 Easy Tips for Healthy Aging 54745 2
... Meeting -, SOUTH SAN FRANCISCO, Calif. and CHICA...aceuticals, Inc. (Nasdaq: PARD ), a biopharmaceut...safety and efficacy results,from a previously unpu...iposomal doxorubicin in patients with advanced sol...strated signals of clinical activity and,acceptabl...
...sented at American Society of Clinical ....J., June 1 Medarex, Inc.,(Nasdaq: MEDX ) today ...survival (OS) results from a Phase 2 clinical stud...ion with dacarbazine (DTIC) where 11.4%, or 4 of,3...years of follow-up. This,included 1 patient that e...
Other Medicine Technology:Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 2Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 3Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 4Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 5Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 2Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 3Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 4
(Date:11/9/2009)...ELES, Nov. 9 Tracy Anderson, train...ate Hudson, will be hosting two events at her LA s...lly sharing her long awaited Nutritional Meal Plan...er TA Baby Food Cleanse and Lifestyle Menu. She w...tes her entire method of cardio and muscle structu...
(Date:11/9/2009)... men and women almost equally, study finds, , ...dely used clot-dissolving drug Plavix (clopidogrel...ysis of major clinical trials has found. , "Aft...eating both men and women with this very important...rdiovascular thrombosis at New York University Lan...
(Date:11/9/2009)...ue to fact that both eye conditions are age-relate...ealthDay News) -- Cataract surgery doesn,t appear ...generation (AMD), according to a new study that ch...ion loss worsens the other. , "Because both con... with cataract also have AMD," wrote Li Ming Dong,...
(Date:11/9/2009)...nted with new cells regained sexual function, stud... News) -- Researchers were able to restore sexual ...g new penile tissue in the lab and implanting it, ...on is a ways off, researchers say the technique co...nction in men. , "We were able to show the tiss...
(Date:11/9/2009)... Fast food chains are often blamed for...nt poll by Fitness.com.au however finds that 80% o...sponsibility. , (PRWEB) N..., and video games were behind Australia’s ob... than just innocent bystanders. A recent survey co...
Breaking Medicine News(10 mins):Health News:Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2
...athologists at The University of Texas Health Scie...modified protein that may help people with a hard-... as Hemophilia A. The discovery and the results of...III), people with Hemophilia A typically receive i...
...nterim results from a nationwide clinical trial le... researcher suggest that radiofrequency ablation i...ith Barretts esophagus, a condition that can lead ...placebo or sham treatment, said Dr. Nicholas Shahe...
...s money and time spent in intensive care units, re...y News) -- Endotracheal tubes coated with silver d...t bacteria, researchers report. , Patients on ven...ed pneumonia. , "Ventilator-associated pneumonia c...
... State University selected as winner, COLUMBUS, O...o 13 colleges and universities across the State of...will be added as registered organ and,tissue donor...ssue and eye,recovery agencies, partnered with the...
...NGTON HEIGHTS, Ill., May 19 Plastic,surgeons perf...ures in 2007,-- ranging from repairing dog bite wo...nstructing breasts following mastectomy., (Photo:...lives?, On average, members of The American Socie...
...rder triggered by gluten in common foods, such as ...DAY, May 19 (HealthDay News) -- New research could...c disease, according to studies presented at the D... small intestine triggered by a protein called glu...
Other Medicine News:Health News:Blood-clotting protein modified for people with hard-to-treat hemophilia 2Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2Health News:Silver-Coated Endotracheal Tubes Cut Down on Infections 2Health News:Silver-Coated Endotracheal Tubes Cut Down on Infections 3Health News:Do It Now College Program Registers Nearly 125,000 New Organ and Tissue Donors 2Health News:Do It Now College Program Registers Nearly 125,000 New Organ and Tissue Donors 3Health News:Each Day, Plastic Surgeons Are Reconstructing Lives: Restoring Function, Improving Appearances, and Elevating Self-Esteem 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 3
... The MNL 440601 Small Sledge Microtome is ideal fo...ally small dental or skin specimens. Specimen ris... setting from 2 30 microns in increments of 2 mic...ng Stages.,Other Associated Products, Vib...
Vibratome Starter Package, 230 Volt, 50/60 Hz
Vibratome Prof. Gold Package, 230 Volt, 50/60 Hz.
Vibratome Professional Package, 230 V. 50/60Hz
Medicine Products: